Venetoclax in Lymphoid Malignancies: New Insights, More to Learn

Publication date: 14 October 2019Source: Cancer Cell, Volume 36, Issue 4Author(s): Rachel Thijssen, Andrew W. RobertsIn this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research